Advertisement

Citations to this article

Abstract

Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis. Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels. In addition, reduction of IL-6 levels by RNA interference led to a decrease in tumorigenesis. Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade. Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased production and release of IL-6. Finally, immunohistochemical analysis revealed a positive correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas. Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.

Authors

Sizhi Paul Gao ... Bayard Clarkson, Jacqueline F. Bromberg

×

Total citations by year

Year: 2015 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 1 41 32 32 29 26 31 15 1 208
Citation information

Citations to this article in year 2012 (32)

Title and authors Publication Year
Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway
HS Hsu, JH Lin, TW Hsu, K Su, CW Wang, KY Yang, SH Chiou, SC Hung
Lung Cancer 2012
Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
ZC Ding, G Zhou
Clinical and Developmental Immunology 2012
Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment
HJ Hugo, S Lebret, E Tomaskovic-Crook, N Ahmed, T Blick, DF Newgreen, EW Thompson, ML Ackland
Cancer Microenvironment 2012
Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling
X Jin, SH Kim, HM Jeon, S Beck, YW Sohn, J Yin, JK Kim, YC Lim, JH Lee, SH Kim, SH Kang, X Pian, MS Song, JB Park, YS Chae, YG Chung, SH Lee, YJ Choi, DH Nam, YK Choi, H Kim
Brain 2012
p14ARF inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway
P Ozenne, D Dayde, E Brambilla, B Eymin, S Gazzeri
Oncogene 2012
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation
D Harada, N Takigawa, N Ochi, T Ninomiya, M Yasugi, T Kubo, H Takeda, E Ichihara, K Ohashi, S Takata, M Tanimoto, K Kiura
Cancer Science 2012
Curcumin Blocks Small Cell Lung Cancer Cells Migration, Invasion, Angiogenesis, Cell Cycle and Neoplasia through Janus Kinase-STAT3 Signalling Pathway
CL Yang, YY Liu, YG Ma, YX Xue, DG Liu, Y Ren, XB Liu, Y Li, Z Li
PloS one 2012
Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology1
ME Loveless, D Lawson, M Collins, MV Nadella, C Reimer, D Huszar, J Halliday, JC Waterton, JC Gore, TE Yankeelov
Neoplasia (New York, N.Y.) 2012
STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
BD Looyenga, D Hutchings, I Cherni, C Kingsley, GJ Weiss, JP Mackeigan
PloS one 2012
ER stress-induced inflammation: does it aid or impede disease progression?
AD Garg, A Kaczmarek, O Krysko, P Vandenabeele, DV Krysko, P Agostinis
Trends in Molecular Medicine 2012
Involvement of STAT3, NF-κB and associated downstream molecules before and after the onset of urethane induced lung tumors in mouse
M Pandey, KP Gupta
Environmental Toxicology and Pharmacology 2012
Interleukin-6 signaling pathway in targeted therapy for cancer
Y Guo, F Xu, TJ Lu, Z Duan, Z Zhang
Cancer Treatment Reviews 2012
DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors
UJ Yun, SE Park, YS Jo, J Kim, DY Shin
Cancer Letters 2012
Acetylation modulates the STAT signaling code
M Wieczorek, T Ginter, P Brand, T Heinzel, OH Krämer
Cytokine & Growth Factor Reviews 2012
Stat3: Linking inflammation to (gastrointestinal) tumourigenesis
M Ernst, TL Putoczki
Clinical and Experimental Pharmacology and Physiology 2012
EGFR inhibitor BIBU induces apoptosis and defective autophagy in glioma cells
R Ghildiyal, D Dixit, E Sen
Molecular Carcinogenesis 2012
A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk
J Chen, RY Liu, L Yang, J Zhao, X Zhao, D Lu, N Yi, B Han, XF Chen, K Zhang, J He, Z Lei, Y Zhou, B Pasche, X Li, HT Zhang
Journal of Cancer Research and Clinical Oncology 2012
Radioimmunoimaging with Mixed Monoclonal Antibodies of Nude Mice Bearing Human Lung Adenocarcinoma Xenografts
D Duan, SL Li, YQ Zhu, T Zhang, CM Lei, XH Cheng
Asian Pacific Journal of Cancer Prevention 2012
STAT3 negatively regulates thyroid tumorigenesis
JP Couto, L Daly, A Almeida, JA Knauf, JA Fagin, M Sobrinho-Simões, J Lima, V Máximo, P Soares, D Lyden, JF Bromberg
Proceedings of the National Academy of Sciences 2012
Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo
S Vicent, LC Sayles, D Vaka, P Khatri, O Gevaert, R Chen, Y Zheng, AK Gillespie, N Clarke, Y Xu, J Shrager, CD Hoang, S Plevritis, AJ Butte, EA Sweet-Cordero
Cancer research 2012
Targeting the interleukin-6/Jak/stat pathway in human malignancies
P Sansone, J Bromberg
Journal of Clinical Oncology 2012
Determinants of the extent and duration of STAT3 signaling
B Groner
JAK-STAT 2012
Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer
MG Alexandrow, LJ Song, S Altiok, J Gray, EB Haura, NB Kumar
European Journal of Cancer Prevention 2012
Pyruvate Kinase M2 Regulates Gene Transcription by Acting as A Protein Kinase
X Gao, H Wang, JY Jenny, X Liu, ZR Liu
Molecular Cell 2012
Curcumin: A Novel Stat 3 Pathway Inhibitor for Chemoprevention of Lung Cancer
MG Alexandrow, LJ Song, S Altiok, J Gray, EB Haura, NB Kumar
European Journal of Cancer Prevention 2012

Advertisement
Advertisement